Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL (co-promoted with Wyeth). The company operates in one business segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2005 |
Three Months Ended June 30, 2004 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|---|
| Total Revenues | $3,172 | $2,585 | $6,005 | $4,928 |
| Product Sales | $3,072 | $2,431 | $5,807 | $4,639 |
| Operating Income | $1,293 | $1,007 | $2,449 | $1,935 |
| Net Income | $1,029 | $748 | $1,883 | $1,438 |
| Diluted EPS | $0.82 | $0.57 | $1.49 | $1.09 |
| Operating Cash Flow (6mo) | $2,340 (2005) vs $1,514 (2004) | |||
| Cash & Marketable Securities | $4,440 (as of June 30, 2005) | |||
| Convertible Notes (Current) | $1,749 (as of June 30, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 23% for the quarter and 22% for the six-month period compared to the prior year. Product sales grew 26% (quarter) and 25% (six months), driven primarily by demand for Aranesp, ENBREL, and Neulasta.
- Profitability: Net income increased 38% for the quarter and 31% for the six-month period. Operating income margins remained stable at approximately 42% of product sales for the six-month periods.
- Legal Settlements: A one-time expense of $49 million was recorded in the second quarter of 2005 related to the settlement of certain legal matters, primarily a patent proceeding. This reduced operating income for the quarter.
- Debt Restructuring: In March 2005, the company repurchased approximately 40% of its outstanding Convertible Notes for $1.175 billion. In May 2005, the remaining notes were exchanged for "Modified Convertible Notes" with different conversion and put terms.
- Stock Repurchases: The company repurchased 39 million shares of common stock for $2.425 billion during the first six months of 2005, compared to 27 million shares for $1.650 billion in the same period in 2004.
Guidance, Outlook, and Risks
- Reimbursement Risks (MMA): The Medicare Modernization Act (MMA) is expected to negatively impact reimbursement rates for Aranesp, Neulasta, and NEUPOGEN in the second half of 2005 due to the shift from Average Wholesale Price (AWP) to Average Sales Price (ASP) methodologies. Management expects ASPs to trend downward through 2005 before stabilizing.
- Expense Outlook: Operating expenses are expected to increase in the second half of 2005 compared to the first half, driven by continued investment in R&D (including AMG 162) and support for product sales growth. SG&A expenses as a percentage of sales are expected to be higher in the second half.
- Supply Constraints: ENBREL sales may be constrained by manufacturing capacity. The company is awaiting FDA approval for a new facility in Rhode Island and EMEA licensure for a facility in Ireland to increase supply.
- Patent Expirations: European patents for erythropoietin have expired, and G-CSF patents expire in August 2006, potentially exposing the company to biosimilar competition in Europe.
- Accounting Changes: The company plans to adopt SFAS No. 123R (Share-Based Payment) on January 1, 2006, which will result in the recognition of stock-based compensation expense, materially impacting future results.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual impact of the MMA ASP changes on Q3 and Q4 2005 sales for Aranesp, Neulasta, and NEUPOGEN.
- ENBREL Supply: Monitor the status of FDA approval for the new Rhode Island manufacturing facility and its effect on ENBREL availability.
- Convertible Notes: Review the terms of the "Modified Convertible Notes" and the potential cash outflow if holders exercise the put option in March 2006.
- Legal Proceedings: Track the status of the Average Wholesale Price (AWP) litigation and other patent disputes mentioned in the filing.
- R&D Pipeline: Assess the progress and clinical trial results for key pipeline candidates, particularly AMG 162, given the increased R&D spending.